Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today the appointment of Stephen J. Forman, M.D., to the Board of Directors of Lixte. Dr. Forman is Director of the T cell Therapeutics Research Laboratory, Director of the Hematologic Malignancies and Stem Cell Transplantation Institute, and holds the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at the City of Hope National Medical Center in Duarte, California. He is co-editor of Thomas' Hematopoietic Cell Transplantation, a definitive textbook for clinicians, scientists and health care professionals.

John S. Kovach, M.D., President and CEO of Lixte, commented, "We are delighted to welcome Dr. Stephen J. Forman to Lixte's Board. Dr. Forman is an internationally recognized leader in preclinical and clinical cancer research. In the past few years, he has expanded his laboratory research to include immunological approaches to cancer. Pharmacological enhancement of patients' immune responses to their cancers is of special interest to Lixte as the enzyme target of its lead clinical compound, LB-100, has been reported recently to be critical to immune function. Dr. Forman's judgment and expertise in cancer drug development will prove an invaluable addition to Lixte as we work towards bringing improved treatments of human cancers and other life-threatening diseases to clinical practice."

About Lixte Biotechnology Holdings, Inc.

Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is completing a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three US Oncology Research sites (see ClinicalTrials.gov: Identifier NCTO1837667).